260 filings
Page 5 of 13
SC 13D/A
msgyjd41w7s5o4y
8 Jan 19
AzurRx BioPharma, Inc.
12:00am
4
lkxdbrugj6o26z 77
7 Jan 19
AzurRx BioPharma / Edmund Burke Jr. Ross ownership change
6:49pm
4
qshbi9faia4 emp
2 Jan 19
AzurRx BioPharma / Johan M. Spoor ownership change
6:47pm
4
omo8fs
2 Jan 19
AzurRx BioPharma / Maged Shenouda ownership change
6:44pm
4
827bce5cb6neo7zcfw6
2 Jan 19
AzurRx BioPharma / EDWARD BORKOWSKI ownership change
6:03pm
4
1oixcm3jxw
2 Jan 19
AzurRx BioPharma / Vern Lee Schramm ownership change
6:01pm
4
ux395yv3
2 Jan 19
AzurRx BioPharma / CHARLES J CASAMENTO ownership change
5:58pm
4
dhe59k7wqicsz
2 Jan 19
AzurRx BioPharma / Alastair Riddell ownership change
5:55pm
8-K
6h65hch4
20 Dec 18
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
5:07pm
8-K
8cu9awz5tw6rr6 j7
13 Dec 18
AzurRx BioPharma to Acquire Payment Rights to Lead
4:39pm
8-K
h33 41ll9pusb5t
5 Dec 18
AzurRx BioPharma to Present at Upcoming Investor Conferences
12:00am
8-K
800nx0i
8 Nov 18
Regulation FD Disclosure
1:46pm
8-K
ee66 vpcq7qt2n54n2
1 Nov 18
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI
3:27pm
8-K
0fq 6u2ta90lmkdcb
22 Oct 18
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019
4:07pm
8-K
a2e1q2bff4jr
2 Oct 18
Regulation FD Disclosure
12:00am
4
5rwibj
1 Oct 18
AzurRx BioPharma / CHARLES J CASAMENTO ownership change
8:05pm
4
4csqq2u
1 Oct 18
AzurRx BioPharma / EDWARD BORKOWSKI ownership change
8:03pm
4
6mnfrep
1 Oct 18
AzurRx BioPharma / Vern Lee Schramm ownership change
7:59pm
4
ngvhr
1 Oct 18
AzurRx BioPharma / Alastair Riddell ownership change
7:56pm